Amer Joseph

TL;DR: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo, and the frequency of adverse events was similar in the two groups.

TL;DR: Finerenone demonstrated a dose-dependent reduction in UACR, and among patients with diabetic nephropathy, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio.

TL;DR: This research presents a novel probabilistic approach that allows us to assess the importance of knowing the carrier and removal status of canine coronavirus, as a source of infection for other animals.

TL;DR: The FIGARO-DKD trial will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.

TL;DR: In this paper, a preclinical model of hypertension-induced end-organ damage was studied in hypertensive, N(ω)-nitro-L-arginine methyl ester-treated, renin-transgenic (mRen2)27 rats, where they were treated once daily orally for up to 7 weeks with placebo, finerenone (1 and 3 mg/kg), empagliflozin (3 and 10 mg/ kg), or a combination of the respective low doses.